| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING FEES | 13,465 | 10,099 | 3,366 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| MERRILL LYNCH SECURITIES | FMV | 6,201,563 | 9,468,138 |
| ADVANCED EQUITIES INVESTMENTS | AT COST | 15,000 | 15,000 |
| IVP CALIENT, LLC | AT COST | 16,007 | 16,007 |
| FRANCISCO PARTNERS INVESTMENTS | AT COST | 173,757 | 173,757 |
| INTUITIVE CALIENT II, LLC | AT COST | 110,079 | 110,079 |
| CYTORI OFFERING | AT COST | 72,300 | 72,300 |
| INVESTMENT - NEUROTROPE BIO SCIENCE INC | AT COST | 108,000 | 108,000 |
| INVESTMENT - ESKSO BIONICS | AT COST | 40,000 | 40,000 |
| INVESTMENT - NEXTLEVEL SECURITY SYSTEMS | AT COST | 25,000 | 25,000 |
| INVESTMENT - PIERIS PHARMACEUTICALS INC | AT COST | 7,759 | 7,759 |
| INVESTMENT - CUR | AT COST | 20,000 | 20,000 |
| INVESTMENT - ENUMERAL EDI | AT COST | 25,000 | 25,000 |
| US VENTURE PARTNERS XI | AT COST | 186,242 | 186,242 |
| INTUITIVE PEERNOVA | AT COST | 110,887 | 110,887 |
| MEDIA | AT COST | 5,000 | 5,000 |
| HISTOGEN INC | AT COST | 30,396 | 30,396 |
| WILSON SONSINI CALIENT | AT COST | 502,750 | 502,750 |
| INTUITIVE INCODEMA 3D | AT COST | 87,752 | 87,752 |
| SPRUCE DIRECT | AT COST | 4,718 | 4,718 |
| ORPHEUS BIOSCIENCE INC | AT COST | 20,000 | 20,000 |
| INNOVATE BIOPHARMACEUTICALS | AT COST | 8,755 | 8,755 |
| INTUITIVE HZO | AT COST | 9,949 | 9,949 |
| OPTICAL CIRCUIT TECH COMPANY | AT COST | 69,079 | 69,079 |
| BLOCK CHANGE TECHNOLOGY | AT COST | 25,000 | 25,000 |
| GROGURU | AT COST | 25,000 | 25,000 |
| CARLSMED INC | AT COST | 25,000 | 25,000 |
| INVESTMENT - US VENTURES XII | AT COST | 153,166 | 153,166 |
| CALIENT HOLDINGS | AT COST | 37,471 | 37,471 |
| INTUITIVE OSTENDO LLC | AT COST | 24,936 | 24,936 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| LEGAL FEES | 483 | 0 | 483 |
| Description | Amount |
|---|---|
| UNREALIZED GAINS/(LOSSES) | 19,096 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| MISCELLANEOUS | 18,189 | 0 | 12,581 | |
| K-1 INVESTMENT LOSSES | 16,084 | 16,084 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| FROM ENTERPRISE PRODUCTS PARTNERS K-1 | 516 | 516 | 516 |
| FROM LITIGATION SETTLEMENT | 119 | 119 | 119 |
| Description | Beginning of Year - Book Value | End of Year - Book Value |
|---|---|---|
| INVESTMENT IN ICHOR HOLDINGS | 6,330 | 6,350 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| INVESTMENT FEES | 92,061 | 92,061 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FRANCHISE TAX | 75 | 0 | 0 | |
| FOREIGN TAX PAID | 2,044 | 2,044 | 0 | |
| FEDERAL TAX | 5,200 | 0 | 0 |